Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients.
No Thumbnail Available
Identifiers
Date
2021-05-20
Authors
González-Salvatierra, Sheila
García-Fontana, Cristina
Andújar-Vera, Francisco
Grau-Perales, Alejandro Borja
Martínez-Heredia, Luis
Avilés-Pérez, María Dolores
Hayón-Ponce, María
Iglesias-Baena, Iván
Riquelme-Gallego, Blanca
Muñoz-Torres, Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Osteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males), and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by ELISA. Linear regression modeling was performed to determine the variables influencing circulating OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to controls (18.41 (14.45-23.27) ng/mL vs. 8.74 (7.03-12.35) ng/mL; p
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
biomarker, diabetic kidney disease, kidney function impairment, osteoglycin, type 2 diabetes